213 related articles for article (PubMed ID: 32778064)
1. Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study.
Jamieson L; Forster MD; Zaki K; Mithra S; Alli H; O'Connor A; Patel A; Wong ICK; Chambers P
BMC Cancer; 2020 Aug; 20(1):743. PubMed ID: 32778064
[TBL] [Abstract][Full Text] [Related]
2. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
[TBL] [Abstract][Full Text] [Related]
3. Association between PD-L1 inhibitor, tumor site and adverse events of potential immune etiology within the US FDA adverse event reporting system.
Abdel-Rahman O
Immunotherapy; 2021 Dec; 13(17):1407-1417. PubMed ID: 34709083
[TBL] [Abstract][Full Text] [Related]
4. Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review.
Shah M; Jomaa MK; Ferrarotto R; Yeung SJ; Hanna EY; Reyes-Gibby CC
Head Neck; 2019 Nov; 41(11):4036-4050. PubMed ID: 31414560
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors.
Arnaud-Coffin P; Maillet D; Gan HK; Stelmes JJ; You B; Dalle S; Péron J
Int J Cancer; 2019 Aug; 145(3):639-648. PubMed ID: 30653255
[TBL] [Abstract][Full Text] [Related]
6. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial.
Levy A; Massard C; Soria JC; Deutsch E
Eur J Cancer; 2016 Nov; 68():156-162. PubMed ID: 27764686
[TBL] [Abstract][Full Text] [Related]
7. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
Bang A; Wilhite TJ; Pike LRG; Cagney DN; Aizer AA; Taylor A; Spektor A; Krishnan M; Ott PA; Balboni TA; Hodi FS; Schoenfeld JD
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):344-351. PubMed ID: 28463153
[TBL] [Abstract][Full Text] [Related]
8. Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study.
Chan SL; Yip TC; Wong VW; Tse YK; Yuen BW; Luk HW; Lui RN; Chan HL; Mok TS; Wong GL
Cancer Med; 2020 Oct; 9(19):7052-7061. PubMed ID: 32780516
[TBL] [Abstract][Full Text] [Related]
9. "Side effects--part of the package": a mixed methods approach to study adverse events among patients being programmatically treated for DR-TB in Gujarat, India.
Jakasania A; Shringarpure K; Kapadia D; Sharma R; Mehta K; Prajapati A; Kathirvel S
BMC Infect Dis; 2020 Dec; 20(1):918. PubMed ID: 33267826
[TBL] [Abstract][Full Text] [Related]
10. Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors.
Gandhi S; Pandey M; Ammannagari N; Wang C; Bucsek MJ; Hamad L; Repasky E; Ernstoff MS
Immunotherapy; 2020 Feb; 12(2):141-149. PubMed ID: 32064978
[No Abstract] [Full Text] [Related]
11. Experience of patients considering or using checkpoint inhibitors in cancer treatment: a systematic review of qualitative research.
Yip R; Arnolda G; Lamprell K; Nic Giolla Easpaig B; Chittajallu R; Delaney G; Olver I; Liauw W; Braithwaite J
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212121
[TBL] [Abstract][Full Text] [Related]
12. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
Ali AK; Watson DE
Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.
Dougan M
Curr Gastroenterol Rep; 2020 Mar; 22(4):15. PubMed ID: 32185493
[TBL] [Abstract][Full Text] [Related]
14. Analysis of adverse events following the treatment of autologous cytokine-induced killer cells for adoptive immunotherapy in malignant tumour sufferers.
Zhang Y; Xia L; Zhang Y; Wang Y; Lu X; Shi F; Liu Y; Chen M; Feng K; Zhang W; Fu X; Han W
Expert Opin Biol Ther; 2015 Apr; 15(4):481-93. PubMed ID: 25435128
[TBL] [Abstract][Full Text] [Related]
15. Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis.
Kiss I; Kuhn M; Hrusak K; Buchler T
ESMO Open; 2022 Jun; 7(3):100474. PubMed ID: 35576697
[TBL] [Abstract][Full Text] [Related]
16. Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review.
Ciner AT; Hochster HS; August DA; Carpizo DR; Spencer KR
Immunotherapy; 2021 Sep; 13(13):1071-1078. PubMed ID: 34287029
[TBL] [Abstract][Full Text] [Related]
17. Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study.
Bar J; Markel G; Gottfried T; Percik R; Leibowitz-Amit R; Berger R; Golan T; Daher S; Taliansky A; Dudnik E; Shulman K; Urban D; Onn A
Eur J Cancer; 2019 Oct; 120():122-131. PubMed ID: 31518968
[TBL] [Abstract][Full Text] [Related]
18. Rheumatic and musculoskeletal disorders induced by immune checkpoint inhibitors: Consequences on overall survival.
Adda L; Batteux B; Saidak Z; Poulet C; Arnault JP; Chauffert B; Séjourné A
Joint Bone Spine; 2021 Jul; 88(4):105168. PubMed ID: 33675979
[TBL] [Abstract][Full Text] [Related]
19. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer.
Rahman MM; Behl T; Islam MR; Alam MN; Islam MM; Albarrati A; Albratty M; Meraya AM; Bungau SG
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744922
[TBL] [Abstract][Full Text] [Related]
20. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
